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Case Report
A 73-year-old woman had undergone a wide local exci-
sion with a 1.5 cm margin for a 3.9 mm thick, non-
ulcerated malignant melanoma located on the right lower 
extremity over the mid tibia.  There was a nodular aggre-
gate of  melanoma cells in the superficial subcutaneous adi-
pose tissue, questionable for a satellite lesion.  Subsequently, 
she underwent a sentinel lymph node biopsy with two of  
four nodes being positive for metastatic disease.  A comple-
tion right inguinal lymphadenectomy found all 13 addi-
tional nodes free of  disease. Metastatic work-up revealed no 
distant disease.   She underwent adjuvant interferon-α2b 
therapy.  After four months of  adjuvant therapy, she devel-
oped multiple small nodules around her original wide local 
excision surgical site.  Biopsy revealed recurrent melanoma 
of  the right lower extremity inferior to the knee surround-
ing the site of  the previous wide local excision (Figure 1).  
She was then referred to our institution for evaluation 
and treatment.  Metastatic work-up was performed.  Posi-
tron Emission Tomography (PET) using 16.1 mCi of  
fluorine-18 Fluorodeoxyglucose (FDG) revealed three focal 
areas of  increased uptake in the skin of  the pre-tibial region 
consistent with the skin lesions found on the physical exam.  
In addition, two focal areas of  increased uptake were noted 
in the subcutaneous tissues posterior and medial to the pre-
vious areas of  wide local excision.  A Magnetic Resonance 
Image (MRI) of  the right lower extremity demonstrated 
two deep lesions in the subcutaneous tissues measuring 4 x 
6 mm and 2 x 5 mm separated by a distance of  3.4 cm 
(Figure 2).  Due to the inability to palpate these two lesions 
on physical exam, it was decided to place radioactive seeds 
for intra-operative localization.
Technique
Radioactive seed localization (RSL) is accomplished with 
a 4.5 x 0.8-mm titanium seed with 100-200 mCi of  125I 
(Cardinal Health, Woodland Hills, CA).  The seed is placed 
into an 18-gauge spinal needle with the tip occluded with 
bone wax and then guided to the lesion(s) under ultrasound 
or stereotactic guidance, in this case using ultrasound for 
each lesion. The seed is then deployed through the bone 
wax with a stylet (Figure 3). Six BB’s were placed on the 
superficial recurrences of  this patient and an AP and lateral 
film performed (Figure 4).  These radiographs in turn were 
used by the surgeon to give a gross estimate of  where the 
lesions are in relation to local landmarks (visible recur-
rences).
The following day the patient underwent a wide local 
excision of  the local recurrence obtaining a 1 cm margin 
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with an immediate free flap reconstruction.  Next, the two 
in-transit metastases were approached. A gamma probe 
(Neo2000, Neoprobe Corporation, Dublin, OH) was used 
to localize the two areas of  highest radioactivity. The 
gamma probe is a hand-held device that is set to detect 
scintigraphic hot spots (i.e. radioactive sentinel lymph nodes 
or radioactive seeds). Due to the close distance between the 
two metastases, one incision was utilized to resect the le-
sions using the gamma probe to provide ongoing feedback.  
Pathologic examination revealed successful excision of  two 
in-transit metastases with a clear margin of  adipose tissue.
Discussion
In 2005, an estimated 59,580 new cases of  melanoma 
were diagnosed and approximately 7770 deaths oc-
curred[1].  Since the 1970’s, melanoma of  the skin has 
steadily increased in incidence, and is now the sixth and 
seventh leading cancer diagnosis in men and women, re-
spectively[1, 2, 3].  In-transit metastases are thought to 
arise from lymphatic seeding of  the subcutaneous tissue 
between the primary lesion and the regional lymph nodes, 
and are distinguished from satellitosis by having a distance 
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Figure 1. Right lower extremity with visible lesions inferior 
to the knee.
Figure 2.  Gadolinium-enhanced fat-saturation T1-weighted MR images of the right lower extremity which depicts one of the 
in-transit metastases seen in the MRI on the left and one of the local/superficial recurrences discovered on Physical Exam 
(PE) seen in the MRI on the right.
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Figure 4.  AP and Lateral films of right lower extremity which displays the gross location of the radioactive seeds in relation to 
the palpable recurrences 
Figure 3.  Sonogram of the right leg (15-MHz probe) dem-
onstrates placement of  a seed into one of the subcutaneous 
melanoma lesions.  Arrows denote the 18 gauge spinal 
needle; arrowhead points to the seed prior to deployment 
into the lesion.
greater than 2 cm from the primary lesion[4].   In-transit 
metastases usually present as small palpable nodules located 
between the primary melanoma site and the lymph node 
basin that receives drainage from the melanoma site.  In 
one study of  over 1500 stage I and II patients, 12.5% of  
patients developed in-transit metastasis[5].  In addition, 
there was an increased risk of  in transit metastases with 
more positive lymph nodes: a 10.8% rate with one positive 
regional node versus a 31.4% rate with three or more posi-
tive regional nodes[5].  
In transit metastases can be associated with significant 
morbidity including bleeding, drainage from necrotic le-
sions, and pain.  The American Joint Committee on Can-
cer stages in-transit metastasis as stage IIIB or IIIC, de-
pending on regional node status with an associated five year 
mortality of  26.7-52.8%[6].  If  possible, surgical excision is 
the treatment of  choice for a small number of  subcutane-
ous in-transit metastases and can be curative[7].  High rate 
of  local recurrence after resection occurs due to the inabil-
ity to remove all metastatic disease.  In the era of  improved 
imaging, smaller and deep subcutaneous lesions are now 
diagnosed.  Surgical removal of  these lesions is difficult due 
to their physically occult nature.  Localization procedures, 
including wire localization or intra-operative ultrasound, 
have inherent limitations.  Herein we report the novel tech-
nique of  RSL of  these lesions. 
Radioactive seed localization has been reported by us 
and others for non-palpable breast lesions with improved 
margin status and patient satisfaction[8,9].  The use of  
RSL for non-palpable breast lesions has resulted in easier 
placement by the radiologist and easier retrieval by the sur-
geon.  The application of  RSL to melanoma has not been 
previously reported. 
With the advent of  PET, MRI, Computed Tomography 
(CT), and high resolution ultrasound, smaller metastatic 
and in-transit lesions are being discovered.  In fact, the 
resolution of  FDG-PET is 5-6 mm, with a 90% sensitivity 
in tumors greater than 78 mm[3] and the smallest tumor 
detected in one study was less than 30mm[3,10].  Often 
times these lesions are nonpalpable.  Since surgical excision 
is the appropriate therapy for a small number of  in-transit 
metastases, localization has become increasingly important 
for the treatment of  metastatic melanoma.
RSL has advantages over other methods of  intraopera-
tive localization such as wire localization and intraoperative 
ultrasound.  With wire localization, generally patients need 
to undergo surgery on the same day as radiographic wire 
placement, while radioactive seeds can be placed the day 
before surgery or longer. This provides improved patient 
convenience and operative and radiologic scheduling. In-
traoperative ultrasound may require the presence of  a ra-
diologist within the operating room suite to help localize 
the lesion if  the surgeon is not trained in ultrasonic evalua-
tion.  This is particularly true for small lesions where visu-
alization is difficult.
In this case of  non-palpable in-transit metastatic mela-
noma, RSL was both effective and technically intuitive. 
RSL has great potential for the localization of  a variety of  
non-palpable lesions. Of  note, the radioactive seed is not 
FDA approved for this procedure; therefore, one needs to 
investigate his/her hospital processes prior to use, including 
nuclear regulatory requirements. 
In summary, RSL proved an effective means of  localiza-
tion of  in-transit metastatic melanoma in this patient and 
should be considered for utilization for this purpose and 
future studies of  wider application.
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